comprehensive -WSS

comprehensive

author：knowledge 2025-08-23 18:37:58 - browse：37

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： A deep dive into Applied Therapeutics’ data, and questions on Cassava

explore

WSS

Amylyx ALS drug fails large clinical trial

Pharma budget tightening trickles down to Doximity

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Sen. Paul opposes bill to ban Chinese biotechs

Precocious puberty in girls comes with mental health risks

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

focus

comprehensive

explore

Supreme Court strikes down use of affirmative action

The history of OxyContin, told through Purdue Pharma documents

The high cost of giving birth even with insurance

Pharma budget tightening trickles down to Doximity

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Medicare proposal to cover medical devices draws a mixed reaction

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Duchenne breakthrough therapy leaves behind pioneering families

Precocious puberty in girls comes with mental health risks

knowledge

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Large hospital system sues Multiplan for low

Where are patients getting their prescriptions for GLP

Kim Kardashian sparks debate on benefits of full

Sen. Paul opposes bill to ban Chinese biotechs

GOP presidential candidates start declaring their loyalty

hotspot

hotspot

explore

entertainment